Perez-Garcia R, et al. - This study investigated if erythropoiesis-stimulating agent (ESA) dose or the typology of the patient is, in any way, related to the reported associations of ESAs with elevated cancer incidence and mortality in haemodialysis (HD) patients. Findings indicated an association of ESA doses of >8000 IU/week with an increased risk of all-cause mortality and hospitalization in HD patients.